爱必妥治疗31例头颈部肿瘤的护理体会
摘要
总结了使用爱必妥治疗31例头颈部肿瘤患者的护理体会,主要包括严格掌握适应征、抢救药品的准备、使用护理、副反应的观察与护理等。本研究31例患者共输注181次爱必妥,治疗全程实施正确、无护理不良事件发生。认为爱必妥作为头颈部肿瘤患者的有效治疗药物,其正确的全程护理是使用爱必妥的关键。
参考文献6
-
1Specenier P, Vermorken JB. Cetuximab in the treatment of squamous cell carcinoma of the head and neck[J].Expert Rev Anticancer Ther,2011,11(4):511-524.
-
2Rivera F, Garcia-Castano A, Vega N, et al. Cetuximab in metastatic or recurrent head and neck cancer:the EXTREME trial[J].Expert Rev Anticancer Ther,2009,9(10):1421-1428.
-
3Kabolizadeh P, Kubicek GJ, Heron DE, et al. The role of ce- tuximab in the management of head and neck cancers[J].Expert Opin Biol Ther,2012,12(4):517-528.
-
4张晓东,张小田,李洁,李健,周军,李燕,沈琳.西妥昔单抗急性输液反应的临床对策[J].肿瘤,2008,28(1):77-79. 被引量:4
-
5Saif MW, Shah M. Kras mutations in colorectal cancer:a practice changing discovery[J].Clin Adv Hematol 0neol,2009,7(1):45-53.
-
6Fakih MG, Wilding G, Lombardo J. Cetuximab induced hypomagnesemia in patients with coloreetal cancer[J]. Clin Colorectal Cancer,2006,6(2): 152- 156.
二级参考文献8
-
1National Cancer Institute-Cancer Therapy Evaluation Program. CTCAE v3.0 [ S/OL]. ( 2005-12-29 ) [ 2007-06-11 ] http://ctep. cancer. gov/reporting/ ctc_v3.0. html.
-
2CUNNINGHAM D, HUMBLET Y, SIENA S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J]. N Engl J Med, 2004,351 (4) : 337 -345.
-
3LENZ H J, VAN CUTSEM E, KHAMBATA-FORD S, et al. Multicenter phase Ⅱ and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines[J]. J Clin Oncol, 2006,24(30) :4914-4921.
-
4SALTZ LB, MEROPOL N J, LOEHRER PJ, et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[ J ]. J Clin Oncol, 2004, 22(7) :1201-1208.
-
5NEEDLE M N. Safety experience with IMCC225, an anti-epidermal growth factor receptor antibody[ J]. Semin Oncol, 2002,29(5 Suppl 14) :55-60.
-
6ROBERT F, EZEKIEL M P, SPENCER SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer[J]. J Clin Oncol, 2001, 19(13) :3234-3243.
-
7PATEL D D, GOLDBERG R M. Cetuximab-associated infusion reactions : pathology and management [ J ]. Oncology, 2006,20 ( 11 ) :1373-1382.
-
8THOMAS M. Cetuximab: Adverse event profile and recommendations for toxicity management [ J ]. Clin J Oncol Nurs, 2005, 9 (3) :332-338.
-
1于晓燕.爱必妥治疗晚期肠癌的护理[J].黑龙江医学,2010,34(11):877-878.
-
2陈青,吴春丽,朱梁军.爱必妥联合伊立替康治疗转移性结直肠癌的护理[J].实用临床医药杂志(护理版),2007,3(4):20-21. 被引量:1
-
3刘英新,王立燕,刘晓霞,王斐,郑成凤,刘英华.爱必妥联合伊立替康化疗致重度骨髓抑制患者的护理[J].实用医药杂志,2011,28(6):524-524. 被引量:1
-
4丘雪琴,黄中英,郑霞.爱必妥联合放化疗治疗肿瘤致不良反应病人的护理[J].全科护理,2009,7(9):793-795. 被引量:1
-
5刘威.爱必妥致结肠癌患者出现不良反应的护理研究[J].中国医科大学学报,2014,43(7):664-665. 被引量:5
-
6张坤芳,黄锋先,叶任高.腹膜透析与血液透析治疗急性肾功能衰竭的比较[J].透析与人工器官,2001,12(2):10-12.
-
7梅英.高压氧在临床治疗中的作用[J].中国现代医学杂志,1998,8(8):74-75. 被引量:1
-
8庄艳玲,王发萍,喻学慧.慢性扁桃体炎患者术前健康教育[J].山东医药,2002,42(36).
-
9王欣.分子靶向药物爱必妥治疗晚期结直肠癌的观察及护理[J].天津护理,2011,19(4):197-198.
-
10北京市红十字基金会爱必妥慈善援助项目——早期获益,长期生存[J].癌症康复,2013(4):85-85.